Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-Month Safety Follow-Up After First Exposure to HP802-247
2013-000949-39Phase 3Completed
- Sponsor
- Smith & Nephew
- Start
- Jun 2013
- Modality
- Cell Therapies, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of HP-802-247 in stasis ulcer and leg ulcer, sponsored by Smith & Nephew. Primary endpoint: Safety follow-up for new and ongoing adverse events. Started Jun 2013; status: completed.
02
Drugs
HP-802-247
03
Conditions
stasis ulcerleg ulcer
Beyond the preview
Go deeper on 2013-000949-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000949-39.